Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

References

• Hideshima T, Anderson K C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2: 927–937
   PubMed Web of Science ®Google Scholar
• Cephalotaxus Research Coordinating Group. Cephalotaxine esters in the treatment of acute leukemia: a preliminary clinical assessment. Chin Med J 1976; 2: 263–272
   PubMed Web of Science ®Google Scholar
• Mai W Y, Lin M F. Induction of apoptosis by homoharringtonine in G1 phase huamn chronic myeloid leukemic cells. Chin Med J 2005; 118: 487–492
   PubMed Web of Science ®Google Scholar
• Jie H, Donghua H, Xingkui X, Liang G, Wenjun W, Xiaoyan H, et al. Homoharringtonine-induced apoptosis of MDS cell line MUTZ-1 cells is mediated by the endoplasmic reticulum stress pathway. Leuk Lymphoma 2007; 48: 964–977
   PubMed Web of Science ®Google Scholar
• Jin W, Di G, Li J, Chen Y, Li W, Wu J, et al. TIEG1 induces apoptosis through mitochondrial apoptotic pathway and promotes apoptosis induced by homoharringtonine and velcade. FEBS Lett 2007; 581: 3826–3832
   PubMed Web of Science ®Google Scholar
• Zhou J, Chen D, Shen Z, Koeffler H P. Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro. Cancer Res 1990; 50: 2031–2035
   PubMed Web of Science ®Google Scholar
• Cai Z, Lin M, Wuchter C, Ruppert V, Dorken B, Ludwiq W D, et al. Apoptotic response to homoharringtonine in human wt p53 leukemia cell is independent of reactive oxygen species generation and implication and implicates bax translocation. Leukemia 2001; 15: 567–574
   PubMed Web of Science ®Google Scholar
• Efferth T, Sauerbrey A, Halatsch M E, Ross D D. Gebhart E. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines. Naunyn Schmiedebergs Arch Pharmacol 2003; 367: 56–67
   PubMed Web of Science ®Google Scholar
• Legha S S, Keating M, Picket S, Ajani J A, Ewer M, Bodey G P. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep 1984; 68: 1085–1091
   PubMedGoogle Scholar
• Neidhart J A, Young D C, Kraut E, Howinstein B, Metz E N. Phase I trial of homoharringtonine administered by prolonged continuous infusion. Cancer Res 1986; 46: 967–969
   PubMed Web of Science ®Google Scholar
• Warrell R P, Jr, Coonley C J, Gee T S. Homoharringtonine: an effective new drug for remission induction in refractory non-lymphoblastic leukemia. J Clin Oncol 1985; 3: 617–621
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Keating M J, Walters R S, Koller C A, McCredie K B, Freireich E J. Phase II study of homoharringtonine in refractory acute myelogenous leukemia. Cancer 1989; 63: 813–817
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Talpaz M, Smith T L, Cortes J, Giles F J, Rios M B, et al. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol 2000; 18: 3513–3521
   PubMed Web of Science ®Google Scholar
• Jin J, Jiang D Z, Mai W Y, Meng H T, Qian W B, Tong H Y, et al. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 2006; 20: 1361–1367
   PubMed Web of Science ®Google Scholar
• Yang X, Yang C, Shao K, Ye X, Meng H, Zhou Y, et al. Refractory multiple myeloma treated with homoharringtonine: report of two cases. Ann Hematol 2007; 86: 919–921
   PubMed Web of Science ®Google Scholar
• Lou Y J, Qian W B, Jin J. Homoharringtonine induces apoptosis and growth arrest in human myeloma cells. Leuk Lymphoma 2007; 48: 1400–1406
   PubMed Web of Science ®Google Scholar
• Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res 2000; 60: 6763–6770
   PubMed Web of Science ®Google Scholar
• Hideshima T, Nakamura N, Chauhan D, Anderson K C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001; 20: 5991–6000
   PubMed Web of Science ®Google Scholar
• Mitsiades C S, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002; 21: 5673–5683
   PubMed Web of Science ®Google Scholar
• Meng H, Yang C, Ni W, Ding W, Yang X, Qian W. Antitumor activity of fludarabine against human multiple myeloma in vitro and in vivo. Eur J Hematol 2007; 79: 486–493
   PubMed Web of Science ®Google Scholar
• Qian W, Liu J, Jin J, Ni W, Xu W. Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1. Leukemia Res 2007; 31: 329–339
   PubMed Web of Science ®Google Scholar
• Guzman M L, Rossi R M, Karnischky L, Li X, Peterson D R, Howard D S, Jordan C T. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005; 105: 4163–4169
   PubMed Web of Science ®Google Scholar
• LeBlanc R, Catley L P, Hideshima T, Lentzsch S, Mitsiades C S, Neuberg D, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62: 4996–5000
   PubMed Web of Science ®Google Scholar
• Kasibhatla S, Tseng B. Why target apoptosis in cancer treatment?. Mol Cancer Ther 2003; 2: 573–580
   PubMed Web of Science ®Google Scholar
• David E, Sun S Y, Waller E K, Chen J, Khuri F R. Lonial S. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood 2005; 106: 4322–4329
   PubMed Web of Science ®Google Scholar
• Specht K, Haralambieva E, Bink K, Kremer M, Mandl-Weber S, Koch I, et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood 2004; 104: 1120–1126
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bergsagel P L, Kuehl W M, Anderson K C. Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104: 603–618
   Web of Science ®Google Scholar
• Liang J, Slingerland J M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003; 2: 339–345
   PubMed Web of Science ®Google Scholar
• Chauhan D, Hideshima T, Rosen S, Reed J C, Kharbanda S, Anderson K C. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J Biol Chem 2001; 276: 24453–24456
   PubMed Web of Science ®Google Scholar
• Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed J C, et al. The AKT kinase is activated in multiple myeloma tunor cells. Blood 2001; 98: 2853–2855
   PubMed Web of Science ®Google Scholar
• Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107: 4053–4062
   PubMed Web of Science ®Google Scholar
• Ghias K, Ma C, Gandhi V, Platanias L C, Krett N L, Rosen S T. 8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: role in induction of apoptosis in multiple myeloma. Mol Cancer Ther 2005; 4: 569–577
   PubMed Web of Science ®Google Scholar
• Rizvi M A, Ghias K, Davies K M, Ma C, Weinberg F, Munshi H G, et al. Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006; 5: 1783–1789
   PubMed Web of Science ®Google Scholar
• Chauhan D, Pandey P, Ogata A, Teoh G, Treon S, Urashima M, et al. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene 1997; 15: 837–843
   PubMed Web of Science ®Google Scholar
• Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies F E, et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 2000; 275: 27845–27850
   PubMed Web of Science ®Google Scholar
• Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann T A, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996; 87: 1104–1112
   PubMed Web of Science ®Google Scholar
• Romashkova J A, Makarov S S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999; 401: 86–90
   PubMed Web of Science ®Google Scholar
• Dan H C, Sun M, Kaneko S, Feldman R I, Nicosia S V, Wang H G, et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004; 279: 5405–5412
   PubMed Web of Science ®Google Scholar
• Nakagawa Y, Abe S, Kurata M, Hasegawa M, Yamamoto K, Inoue M, et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 2006; 81: 824–831
   PubMed Web of Science ®Google Scholar